Articles tagged with Personalized Medicine
A recent study from the University of Eastern Finland examines how companies participate in personalized medicine development and identifies three main ways to frame its future. The findings highlight the importance of ongoing dialogue and shared understanding among stakeholders to align goals and perspectives.
A genomic study found two previously unreported truncating germline variants in BRCA2, suggesting inherited alterations may contribute to susceptibility to multiple primary lung cancers. The study also points toward important clinical applications, including the use of PARP inhibitors and molecularly targeted approaches for treatment.
A CU Anschutz study reveals reduced mitochondrial efficiency in healthy yet sedentary individuals, which may precede the development of major diseases like cancer, diabetes, and Alzheimer's. Regular exercise acts as a literal shield for cellular health, helping mitochondria seamlessly switch between burning fat and carbohydrates.
Researchers evaluated two somatostatin receptor PET tracers for breast cancer treatment, found SSTR-positive tumors in many estrogen receptor-positive cases. A new PET tracer showed promise for detecting Staph infections, while an interim PET scan may help track response to PSMA therapy in advanced prostate cancer.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Scientists have identified a unique chimeric RNA called UBA1-CDK16 that plays important roles in women's blood cell development and disease severity. The findings suggest the chimeric RNA may serve as a natural brake to protect women from excessive autoimmune activity.
Researchers found that patients often wait an average of four weeks for biomarker test results, with the first step taking up to 23 days to order testing. This delay can lead to mismatched therapies, toxic side effects, and reduced treatment options, emphasizing the need for improved testing turnaround times.
A spatial map of muscle-invasive bladder cancer reveals organized tumor cell states, immune environments, and therapeutic vulnerabilities. Luminal-like cells are found in tumor cores with relevant therapeutic markers, while basal-like cells near margins show signs of aggressiveness. This study guides treatment strategies by accounting ...
Researchers found that over-the-counter probiotics contain only 36 unique species of bacteria, with most common species being forms of Lactobacillus. The analysis suggests a lack of consistency in the combination of species used to support gut health and vaginal health claims.
A new clinical trial, SELECTmeso1, is investigating a personalized treatment for patients with a rare and aggressive form of cancer. The trial aims to improve outcomes for patients with a specific genetic biomarker, and if successful, could lead to future practice-changing trials.
Researchers found that patients with Medicare Advantage insurance were more likely to receive certain types of stroke-preventing care and recover faster from strokes. In contrast, patients on traditional Medicare received more intensive post-stroke care and rehabilitation.
The University of Virginia has joined SPARK GLOBAL to leverage resources and expertise in accelerating the development of new medicines. This collaboration aims to reduce time from lab discoveries to clinic trials, delivering tangible healthcare solutions to patients.
Researchers created a personalized adaptive DBS system that detects neural signals associated with each step and adjusts stimulation in real time, improving gait symmetry and reducing falls. The study demonstrates the potential for brain stimulation to adapt to behavior itself, opening doors to future therapies.
The review systematically maps out the research landscape of wearable AI doctors, combining power-harvesting approaches with self-powered intelligence. Flexible electronics enable devices to withstand dynamic environments, while on-device AI inference processes data locally for real-time analysis.
Research on targeted radioactive gold nanoparticles shows promise against aggressive brain tumors. Ultra-high-resolution PET scanners provide detailed views of mouse brains. New imaging tracers target key drivers of prostate cancer growth.
The FDA has accepted Genentech's supplemental Biologic License Application for atezolizumab, supported by phase III ATOMIC trial results. The trial showed a 50% reduction in cancer recurrence or death and 86.3% disease-free survival rate.
A novel study utilizing sharing circles reveals the need for holistic strategies that blend Indigenous and Western approaches to overcome systemic barriers. Key findings include the central role of humor as a culturally grounded mode of communication and the importance of storytelling in traditional teachings.
A new vertical design separates expensive electronic components from disposable plastic patches, allowing sweat to travel upward and make electrical contact with sensors. This separation prevents waste and makes continuous monitoring economically possible.
A team of researchers has made a significant contribution to understanding human genetics by mapping the Japanese genome, revealing new insights into genetic disease shaping in the Japanese population. The study nearly doubled the complete reconstruction rate to 91.2%, enabling better personalized medicine and treatment options.
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
The Journal of Nuclear Medicine has published several groundbreaking studies on targeted radiotherapy approaches for various types of cancer. Researchers have successfully identified tumors using fibroblast activation protein (FAP)-targeting compounds and explored the potential of PET/MRI scans in detecting endometriosis and recurrent ...
Researchers discover that breast cancer cells exploit protective systems in bone marrow to remain dormant, using Notch2 signaling and genes like CXCR4 and TIE2. This dormancy allows cells to reactivate years later, leading to secondary tumors.
The FUTURE-D project combines data science with clinical expertise to identify warning signs of depression earlier, enabling more targeted interventions. Researchers will integrate longitudinal cohort data from the MACS and NESDA studies to better understand depressive disorders.
The SNMMI 2026 Annual Meeting showcased significant advancements in precision nuclear medicine, AI, theranostics, and molecular imaging. The meeting featured over 1,500 abstracts, a 25% increase from last year's meeting, and presented new educational sessions alongside networking opportunities.
A new study found that demand for abortion and miscarriage hotlines increased by double digits before the Dobbs decision, with states later enacting abortion bans seeing a significant surge. The hotline saw a 210% spike in use from June 2022 to June 2023.
Jason Lewis, PhD, FSNMMI, has been elected as SNMMI's vice president-elect. He aims to strengthen education, scientific exchange, and outreach efforts to integrate basic scientists into SNMMI programs. Lewis holds various academic and research positions.
A new end-to-end PET imaging approach for osteosarcoma distinguishes tumor tissue from normal tissue and assesses surgical margins in real-time. The platform enables precise tumor resection, reducing the risk of local recurrence and preserving maximum limb function.
Gary Ulaner, a renowned nuclear medicine expert, has been elected president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He aims to advance SNMMI's Mars Shot initiative, expand educational activities for professionals, and increase funding for training new radiochemistry and physics specialists.
Researchers used an open-source AI model called Mirai to quickly identify high-risk patients and expedite their diagnostic process. This led to a significant reduction in wait times, with some women receiving biopsy results within days of having their mammograms done.
Heather Jacene, MD, has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), with a focus on strengthening the organization and advancing nuclear medicine. She plans to create new opportunities for members to participate actively in SNMMI and conduct multidisciplinary collaborations.
A new PET imaging approach measures synaptic density in the spinal cord, allowing physicians to monitor disease progression and evaluate treatment effectiveness. This technique detects widespread reductions in synaptic connections across the brain and spinal cord in patients with multiple sclerosis.
Researchers have identified RET as a biomarker for neuroendocrine prostate cancer and developed a theranostic pair for PET imaging and radioligand therapy. The approach demonstrates high uptake in tumors and shows promise for treatment, offering an alternative to current PSMA-based imaging.
Dr. Martin G. Pomper has been awarded the 2026 Benedict Cassen Prize for his outstanding contributions to nuclear medicine, particularly in the development of PSMA-targeted agents. His work has led to significant advances in cancer diagnosis and treatment, including the creation of commercial PSMA-targeted PET agents.
A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC). The tracer successfully identified additional metastatic lesions missed by standard imaging while reducing abdominal background noise.
A novel PET imaging framework reveals bariatric surgery induces coordinated changes in metabolic function across organs, including fat, liver, pancreas, muscle, and immune-endocrine organs. These findings support the use of whole-body PET/CT as a tool to map organ-level metabolic health.
A new type of peptide receptor radionuclide therapy (PRRT) shows promise in treating metastatic neuroendocrine tumors. The novel approach resulted in partial remission in the majority of patients with advanced cases, with manageable safety and encouraging antitumor activity.
Researchers developed a novel PET imaging approach to detect immune-related adverse events in patients receiving immunotherapy. The approach uses CCR2-targeted radiotracer to visualize both tumor progression and cardiac inflammatory responses. Co-treatment with itacitinib improved tumor response while reducing cardiac inflammation.
Dr. Richard E. Carson has made significant contributions to the understanding and application of nuclear medicine, particularly in neuroscience and neuropsychiatric disorders. His work led to the development of diverse tracer kinetic modeling techniques and innovative imaging systems like NeuroEXPLORER.
A study found that a specific pattern of brain metabolism visualized with PET imaging can predict which patients are most likely to benefit from Alzheimer's disease therapy. Patients with this pattern experienced stabilized cognitive performance, while those with other patterns had significant cognitive decline.
A new SPECT/CT imaging approach can accurately differentiate between inflammation and fibrosis in interstitial lung disease (ILD) patients. Researchers used the molecular imaging agent ⁹⁹ᵐTc-maraciclatide to visualize inflammation, which is crucial for determining treatment decisions.
Johnson aims to protect and advance the scope of practice for nuclear medicine technologists, strengthening the national workforce pipeline through education-driven partnerships with industry. She will also formalize standardized training resources as new technologies are introduced.
Irène Buvat, a pioneering researcher, has received the SNMMI's George Charles de Hevesy Nuclear Pioneer Award for her groundbreaking work in molecular imaging quantification. Her contributions have led to improved diagnosis and treatment of cancer through the development of simulation and radiomics tools.
Researchers developed a new tau PET radiotracer that can accurately detect chronic traumatic encephalopathy (CTE) in living patients. The tracer's ability to bind to tau pathology was confirmed in post-mortem CTE tissue, and preliminary results suggest it could provide an early diagnostic biomarker for the disease.
PSMA PET scans have been shown to detect bone metastases that conventional imaging misses, resulting in faster disease progression and worse overall survival. Patients with these undetected lesions are at a higher risk of progressing to treatment-resistant cancer and dying sooner.
Shannon Youngblood has been elected as the new president of the SNMMI Technologist Section. She will focus on amplifying visibility through advocacy, building a more inclusive workforce through educational opportunities, and streamlining professional development to stay current with advancements in theranostics and cardiac PET-CT.
The Society of Nuclear Medicine and Molecular Imaging recognized six new Fellows for their exceptional contributions to the field. The SNMMI Fellowship honors members who have demonstrated excellence in scientific discovery, educational efforts, or clinical practice.
Vasken Dilsizian, MD, has received the Minoshima-Pappas Transformational Leadership Award for his vision and leadership in advancing nuclear medicine and molecular imaging. He has made significant contributions to the field of cardiovascular diseases through his innovative scientific work.
A new machine-learning model uses pre-therapy PET/CT scans to estimate radiation dose to tumors and healthy organs, improving patient selection and reducing toxicity risk. The study's findings suggest a promising ability to predict post-therapy dosimetry, which may optimize treatment plans for individual patients.
The American Cancer Society has endorsed two new types of stool tests and recommends limiting the use of blood tests for colorectal cancer screening. The guidelines aim to encourage people to get screened while improving detection rates.
3D printed anatomical models are being used to improve surgical outcomes in complex and delicate structures. Medical 3D printing technologies also create highly personalized implants and prostheses, supporting better surgical outcomes and post-operative results.
Researchers have made significant breakthroughs in nuclear medicine, with studies revealing uneven radiation doses in tiny kidney structures, improving survival rates for prostate cancer patients through targeted radiation therapy, and developing a new PET imaging approach to detect abdominal cancer spread. These advancements aim to im...
The American College of Cardiology has issued a new Expert Consensus Decision Pathway to guide postpartum cardiovascular care, emphasizing comprehensive visits and effective management of CV emergencies. The guideline aims to reduce maternal morbidity and mortality by optimizing cardiometabolic outcomes.
Philip Tai, PhD, received a $1.6 million grant to investigate AAV vector mechanisms using high-resolution DNA sequencing technology. His findings could lead to new vector designs that improve gene therapy treatments' safety. The goal is to remove mutations that cause cancer-causing integration into host cells.
A machine-learning guided lifestyle coaching program based on data collected via personal devices reduced depressive symptoms by six weeks. Participants who implemented the program experienced significant reductions in depressive symptoms and the treatment effect persisted during three months after the intervention ended.
The UMass Center for Clinical and Translational Science has received a seven-year, $50 million grant from the NIH. The funding supports collaboration among researchers at multiple UMass campuses and clinical partners.
The MAF Test predicts breast cancer prognosis and helps identify patients who may benefit from treatment. In South Korea, the test could improve survival rates for approximately 34,000 newly diagnosed breast cancer patients each year.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
Researchers have developed a targeted radiopharmaceutical treatment that can effectively slow tumor growth in pancreatic ductal adenocarcinoma, achieving complete remission in preclinical models. The treatment targets CD44v6 expression and has shown promise as a new option for patients with this highly aggressive cancer.
IEC-HS is a rare but potentially fatal complication of CAR-T therapy, characterized by sustained inflammatory response and distinct biochemical differences from CRS. Targeted therapies, such as interleukin-1 blockade, are gaining attention for its management.